A touchscreen interface will control the next generation of PACS, if Image Technology Laboratories has its way. The Kingston, NY, company has developed such an interface to control diagnostic monitors in its own PC-based PACS. Spurring development of the
A touchscreen interface will control the next generation of PACS, if Image Technology Laboratories has its way. The Kingston, NY, company has developed such an interface to control diagnostic monitors in its own PC-based PACS. Spurring development of the interface were the clinical preferences of the company’s president and CEO, Dr. David Ryon.
“As a radiologist, I needed more flexibility and ease of operation than was available through current PACS vendors,” Ryon said.
PACS productivity is impaired by having GUI (graphical user interface) controls built into each monitor, he said. These controls are run by mouse interfaces that become ever more cumbersome as more monitors are added.
Image Technology collected all the GUI controls present on individual monitors and placed them on a single touchscreen controller positioned in front of the radiologist. The system supports simultaneous viewing of hundreds of images yet maintains individual control over the display screens.
“This allows us to have rapid navigation through the system, since touchscreen monitors are extremely fast, reliable, and intuitive,” Ryon said. “That’s why they’re used in many industries like fast food. You just touch the screen for the next operation you want to go through.”
The approach has the added benefit of optimizing screen space on display monitors. Removing control bars or similar GUIs across the top or down the side of those monitors opens enough space for a row or column of images, Ryon said.
Working with Dr. Carlton T. Phelps, a radiologist and software developer, and Lewis M. Edwards, a member of IBM’s senior technical staff, Ryon built the PACS around Windows 2000. The system supports most medical and software design interoperability standards, including DICOM, HL7, ODBC, HTML, TCP/IP, CORBA, and Microsoft DNA. One beta site is already operating, and the company plans to begin marketing the system in the third quarter of this year.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.